Skip to main content
. 2019 Nov 15;25(1):165–174. doi: 10.1007/s10147-019-01545-4

Fig. 2.

Fig. 2

TTD in HRQoL in Japanese patients (ITT population) with advanced or metastatic urothelial carcinoma treated with pembrolizumab (n = 30) or chemotherapy (n = 22). HRQoL health-related quality of life, ITT intent-to-treat, TTD time to traditional deterioration